Bone Loss in Patients with Inflammatory Bowel Disease Is Less Than Expected: A Follow-up Study

References

• Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with bowel disease. Gut 1997;40:228–33.
   Google Scholar
• Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71–6.
   Google Scholar
• Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031–9.
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313–9.
   PubMed Web of Science ®Google Scholar
• Nuti R, Martini G, Gennari C. Age-related changes of whole skeleton and body composition in healthy men. Calcif Tissue Int 1995;57:336–9.
   Google Scholar
• Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Exp Clin Endocrinol Diab 1994;102:44–9.
   Google Scholar
• Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflammatory Bowel Dis 1998;4:268–75.
   PubMedGoogle Scholar
• Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417–22.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Herrmann A, Göke M, Manns MP, von zur Mühlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157–63.
   Google Scholar
• Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel desease. Gut 1988;29:1332–6.
   Google Scholar
• Clements D, Motley RD, Evans WD, Harries AD, Rhodes J, Coles RJ, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055–60.
   PubMed Web of Science ®Google Scholar
• Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23: 95–104.
   PubMedGoogle Scholar
• Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn’s disease. Scand J Gastroenterol 1997;32:226–32.
   PubMed Web of Science ®Google Scholar
• Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease: a propective study. Osteoporosis Int 1995;5:156–60.
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC. Markers of bone marrow resorption predict hip fracture in elderly women: the Epidos prospective study. J Bone Min Res 1996;11:1531–8.
   Google Scholar
• Chesnut CHI, Bell NH, Clark GF, Drinkwater BL, English SC, Johnston CC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagenmonitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29–37.
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Min Res 1997;12:624–31.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D, DeSonto SM. Coated mesalazine (5-aminosalicylic acid ) versus Sulphalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989;298:82–6.
   PubMed Web of Science ®Google Scholar
• Singleton JW, Kern F, Best WR, Becktel JM. Development of a Crohn’s disease activity index. Gastroenterology 1976;70:439–44.
   PubMedGoogle Scholar
• Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992;7:1251–8.
   Google Scholar
• Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046–52.
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Min Res 1996;11: 337–48.
   PubMed Web of Science ®Google Scholar
• Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736–46.
   PubMed Web of Science ®Google Scholar
• Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543–6.
   PubMed Web of Science ®Google Scholar
• Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235–42.
   Google Scholar
• Neef B, Maier K-E, von Gaisberg U. Schwere Osteoporose bei einer jungen Patientin mit Morbus Crohn. Dtsch Med Wochenschr 1991;116:1055–60.
   PubMedGoogle Scholar
• McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 1998;128: 253–61.
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide–bound bone cross-links excretion. J Bone Min Res 1995;10:641–9.
   Google Scholar
• Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994;78:955–9.
   Google Scholar
• Marshall LA, Cain DF, Dmowski WP, Chesnut CH. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol 1996;87:350–4.
   PubMed Web of Science ®Google Scholar
• Ravn P, Christiansen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998;22:559–64.
   PubMed Web of Science ®Google Scholar
• Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996;38:223–8.
   PubMedGoogle Scholar
• Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995;9: 237–50.
   PubMed Web of Science ®Google Scholar